Knowledge Library

AAV vectors are widely used in gene therapy, largely because they do not become integrated into the patient’s DNA and are safe from an immunogenicity perspective. AAVs also offer great versatility, with different targets possible using different serotypes. Relative to other vectors, AAVs are also generally produced at higher titers, which reduces costs. In addition, …Read More >

  Advancements in next-generation cell and gene therapies are fulfilling the promise of personalized medicine and attempting to cure and heal patients. Multiple approved products have been launched in global markets and the number of clinical trials continues to grow. Developing innovative advanced therapies is one of the biopharmaceutical industry’s greatest opportunities to dramatically improve …Read More >

  In January, Phacilitate Leaders World & World Stem Cell Summit 2020 brought together the entire ecosystem of the advanced therapies industry from all corners of the globe to continue to build strong partnerships and collaborations to Miami, FL.  Phacilitate team spoke to Felix Hsu, Senior Vice President and Global Head at WuXi Advanced Therapies about strategically looking …Read More >

  This article features: Bai-wei Gu, Head of the Cell Line Development Group, Juan Lagos, Head of Upstream Processing, and Matthew Weaver, Head of Downstream Processing at WuXi Advanced Therapies covering how to accelerate development and manufacturing platforms for viral vectors. Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ …Read More >

WuXi AppTec’s enabling capabilities and contribution to the development of life science were recognized by both its many partners and the City of Philadelphia at the BIO International Convention 2019. The BIO International Convention is hosted annually by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers …Read More >